CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 12, 2011
Result type: Reports
Project Number: SR0262-000
Product Line: Reimbursement Review

Generic Name: Asenapine

Brand Name: Saphris

Manufacturer: Lundbeck Canada Inc.

Therapeutic Area: Schizophrenia

Indications: Schizophrenia

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: June 14, 2012

Recommendation Type: Do not list